Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02024646 | Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis | PHASE3 | COMPLETED | 484 | — | — | Mar 1, 2014 | Oct 1, 2015 | Aug 20, 2020 | 103 | United States, Canada +8 |
ACR20 is used as a measurement of the proportion of subjects who are reaching a 20% improvement of tender an swollen joint counts. The higher percent of subjects reaching a higher improvement percentage shows greater success.
| Arm | Type | Description |
|---|---|---|
| 210 mg brodalumab | EXPERIMENTAL | Administered via subcutaneous injections. |
| 140 mg brodalumab | EXPERIMENTAL | Administered via subcutaneous injection. |
| Placebo | PLACEBO_COMPARATOR | Administered via subcutaneous injection until week 24. |
| Name | Type | Description |
|---|---|---|
| 210 mg brodalumab | DRUG | 210 mg brodalumab administered via subcutaneous injection. |
| 140 mg brodalumab | DRUG | 140 mg brodalumab administered via subcutaneous injection. |
| Placebo | DRUG | Placebo administered via subcutaneous injection until week 24. |
Inclusion Criteria: Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least 1 psoriatic skin lesion. Exclusion Criteria: • -Subjec...